Combined bevacizumab and erlotinib treatment in patients with lung cancer with the T790M resistance mutation
Mené dans 8 pays européens sur 109 patients atteints d'un cancer du poumon non à petites cellules de stade avancé présentant une mutation du gène EGFR, cet essai de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité d'un traitement combinant erlotinib et bévacizumab, en fonction de la présence concomitante d'une mutation T790M du gène EGFR avant le traitement
Non-small-cell lung carcinoma (NSCLC) harbouring activating mutations of the epidermal growth factor receptor (EGFR) gene are extremely sensitive to EGFR tyrosine kinase inhibitors such as erlotinib.1 However, virtually all such tumours start to regrow after approximately 10 months of treatment owing to acquired resistance; roughly half of acquired resistance is attributable to a secondary mutation in the EGFR gene (T790M), which increases the affinity of EGFR for ATP relative to that for tyrosine kinase inhibitors.
The Lancet Respiratory Medicine , commentaire, 2016